USPTO trademark

MAZE

AllowedUSPTOWord markClass 1Class 5Class 42

"MAZE" is a word mark owned by Maze Therapeutics, Inc., filed at the USPTO on October 21, 2024. It has been allowed and covers classes 1, 5 and 42.

View Maze Therapeutics, Inc. portfolioGet this data via the API
Official USPTO record
MAZE trademark as filed
As filed with the USPTO
Status
Allowed
Since July 27, 2026
Filed
October 21, 2024
Registered
Not yet
Expires
Not recorded
Application no.
98811175
Registration no.
Not yet
Office
USPTO
United States Patent and Trademark Office
Mark type
Word mark
3 classes
Ownership

Who owns MAZE

The owner on file, matched to the company behind it. Every owner-name spelling for that company is grouped on its page.

Owner

Maze Therapeutics, Inc.

MAZE · South San Francisco, United States

5 trademarks in the portfolioView company

Representative

Joyce Liou

Morrison & Foerster LLP

Goods and services

What the mark covers

The products and services MAZE is filed for, grouped by Nice class.

  • Diagnostic preparations for scientific or research use other than for medical use; assays and reagents for scientific or medical research use; genetic testing preparations for scientific or medical research use, namely, assays and reagents for use in genetic and biomedical research; cells for scientific or medical research use

  • Anti-infectives; anti-inflammatories; antibacterial pharmaceuticals; antibiotics; antifungal preparations; antivirals; cardiovascular pharmaceuticals; dermatological pharmaceutical products; pharmaceutical preparations for treating genetic diseases and disorders; pharmaceutical preparations for treating lysosomal storage disorders; pharmaceutical preparations acting on the central nervous system; pharmaceutical preparations for the prevention and treatment of gastro-intestinal diseases; pharmaceutical preparations for the prevention and treatment of diseases and disorders of the autoimmune system, the metabolic system, the endocrine system, the musculoskeletal system, and the genitourinary system; pharmaceutical preparations for use in hematology and in tissue and organ transplantation; pharmaceutical preparations for the prevention and treatment of eye diseases and conditions; pharmaceutical preparations for the prevention and treatment of heart diseases and disorders; pharmaceutical preparations for the prevention and treatment of immune system related diseases and disorders; pharmaceutical preparations for the prevention and treatment of kidney diseases and disorders; pharmaceutical preparations for the prevention and treatment of diabetes; pharmaceutical preparations for the prevention and treatment of hypertension; pharmaceutical preparations for the prevention and treatment of skin disorders; pharmaceutical preparations for use in urology; pharmaceutical preparations for the prevention and treatment of obesity; pharmaceutical preparations for ophthalmological use; pharmaceutical preparations for the prevention and treatment of cancer and tumors; pharmaceutical preparations for the prevention and treatment of allergies; pharmaceutical products for the prevention and treatment of bone diseases; pharmaceutical products for the prevention and treatment of respiratory diseases and asthma; reagents for medical use; genetic testing preparations for medical purposes, namely, medical diagnostic reagents and assays for testing of body fluids; cells for medical or clinical use; medical diagnostic and testing assays, namely, medical diagnostic reagents and assays for testing of body fluids

  • Pharmaceutical research and development services; research in the field of genetic modifiers and related therapeutics for genetic diseases; research in the field of genetic variations linked to medical diseases or conditions; research in the field of variant functionalization

History

What has happened so far

Steps recorded by the USPTO, newest first.

  1. Notice of approval of extension request e-mailed
  2. Sou extension 1 granted
  3. Sou extension 1 filed
  4. Sou teas extension received
  5. Noa e-mailed - sou required from applicant
  6. Official gazette publication confirmation e-mailed
  7. Published for opposition
  8. Notification of notice of publication e-mailed
  9. Approved for pub - principal register
  10. Examiner's amendment entered

10 earlier steps on the official record.

FAQ

About MAZE

Who owns the trademark "MAZE"?

The USPTO trademark "MAZE" (application 98811175) is owned by Maze Therapeutics, Inc.

What is the status of "MAZE"?

Its status at the USPTO is: allowed.

API

Get this data via the API

Everything on this page comes from the Signa API. Pull MAZE and marks like it into your own product with one request.

  • GET/v1/trademarks/{id}

    The full record: owners, classes, dates and images

  • GET/v1/trademarks/{id}/events

    Every step in the office history

  • GET/v1/proceedings?trademark_id={id}

    Oppositions and cancellations against the mark

Get API keyView docs
GET /v1/trademarks/{id}
ID=tm_019d29fc-6804-7799-a709-cc7ffabc4f2f
curl https://api.signa.so/v1/trademarks/$ID \
  -H "Authorization: Bearer $SIGNA_API_KEY"
Response
{
  "id": "tm_019d29fc-6804-7799-a709-cc7ffabc4f2f",
  "object": "trademark",
  "mark_text": "MAZE",
  "status": {
    "primary": "pending",
    "stage": "allowed"
  },
  "office_code": "US",
  "application_number": "98811175",
  "filing_date": "2024-10-21",
  "nice_classes": [
    1,
    5,
    42
  ],
  "owners": [
    {
      "name": "Maze Therapeutics, Inc.",
      "entity_id": "ent_019eb70d-2844-77d7-bd0f-5ecfccafdb72"
    }
  ]
}